Abstract: Registration of images includes rotational and translation correction. Rotational correction includes estimating a rotational-correction angle by polar K-space cross-correlation. K-space regridding is used to rotate an image by the estimated correction angle. Translational correction is obtained by K-space phase-plane conjugation.
Type:
Grant
Filed:
April 29, 1996
Date of Patent:
December 15, 1998
Assignee:
The McLean Hospital Corporation
Inventors:
Luis C. Maas, III, Blaise deB. Frederick, Perry F. Renshaw
Abstract: Disclosed is a transgenic non-human mammal that expresses in its brain a transgene encoding an APP-C100 polypeptide with the flag amino acid sequence fused to the amino terminus of the APP-C100. This transgenic non-human mammal is an improved in vivo model for Alzheimer's disease-like neuropathology and associated cognitive impairment. The improvement includes accelerated development of AD-like neuropathology and cognitive impairment. The AD-like neurodegeneration and associated cognitive impairment in mice produced according to this invention appear at least six months sooner than they appear in APP-C100-expressing transgenic mice.
Type:
Grant
Filed:
October 16, 1996
Date of Patent:
December 15, 1998
Assignees:
The McLean Hospital Corporation, Wellesley College
Abstract: The invention provides a method of diagnosing Alzheimer's disease in a human patient by measuring the amount of p33 present in a biological sample from a patient who may have Alzheimer's disease relative to the amount of p33 in a control sample from an unaffected human. Also included in the invention are diagnostic kits for Alzheimer's disease and methods of screening for effective therapeutics for Alzheimer's disease.
Abstract: Disclosed is a method of diagnosing Alzheimer's disease in a patient by measuring the level of cathepsin D in the patient's cerebrospinal fluid.
Abstract: This invention is directed to two highly purified neural calcium-activated neutral proteinase (CANP or calpain) inhibitors, known as high molecular weight calpastatin (HMWC) and low molecular weight calpastatin (LMWC). The invention also relates to recombinant DNA molecules which code for, and antibodies which bind to these proteins. The present invention is further directed to the use of these calpastatin proteins.
Abstract: Methods for screening individuals for Alzheimer's disease are disclosed. Also disclosed are antibodies that immunochemically react with the isoforms of calcium-activated neutral proteinases which are characteristic of Alzheimer's disease. Also disclosed are methods for screening drugs which are useful in treating or preventing Alzheimer's disease.
Abstract: The invention relates to an in vitro method of screening for drugs, potentially useful for treatment of Alzheimer's Disease. The method involves contacting a drug with a host transformed with a DNA construct which contains at least the DNA coding for human A4-amyloid peptide and overexpresses the peptide and then detecting the prevention of production or increased degradation of the A4-peptide due to the drug.
Type:
Grant
Filed:
December 15, 1992
Date of Patent:
August 20, 1996
Assignees:
The McLean Hospital Corporation, University of Rochester
Abstract: This invention is directed to two highly purified neural calcium-activated neutral proteinase (CANP or calpain) inhibitors, known as high molecular weight calpastatin (HMWC) and low molecular weight calpastatin (LMWC). The invention also relates to recombinant DNA molecules which code for, and antibodies which bind to these proteins. The present invention is further directed to the use of these calpastatin proteins.
Abstract: The invention relates to an assay for one or more analytes which comprises contacting a sample suspected of containing one or more analytes with a solid phase containing one or more different antigen specific antibodies separately immobilized to defined areas on the solid phase, followed by indirectly detecting the presence of bound antigen by titrating the unbound immobilized antibodies with a titrating antibody which is specific for the first antibody. This assay allows the simultaneous detection of a multiplicity of antigens in a single assay.
Abstract: Mixed opiate agonist/antagonists, particularly buprenorphine, is provided for the treatment of cocaine dependence and concurrent cocaine and opiate abuse and dependence.
Abstract: Ester derivatives of gamma-aminobutyric acid (GABA) and GABA analogues which cross the blood-brain barrier are disclosed, as well as methods of synthesizing and using the compounds.The ester derivatives have the formula: ##STR1## where A is a radical compound having at least one esterifiable OH group; n varies from one to the total number of esterifiable OH group contained in A; and R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are hydrogen or a substituent.
Abstract: This invention is directed to a method for assessing hypothalamic function and anterior pituitary hormone function comprising administering 14-hydroxydihydronormorphinone derivatives to a patient in an amount sufficient to stimulate the secretion of anterior pituitary hormones in said patient and assessing the level of secreted hormone.